Article
Gastroenterology & Hepatology
Piero Vernia, Monica Cesarini, Aurora de Carolis, Filippo Vernia
Summary: This study aimed to investigate the prevalence of early hydrogen peaks during lactose breath tests and the proportion of patients affected by SIBO. The results showed that early hydrogen peaks are rarely associated with SIBO, and the finding does not help identifying high-risk patients for this condition.
DIGESTIVE AND LIVER DISEASE
(2021)
Article
Gastroenterology & Hepatology
David J. Cangemi, Brian E. Lacy, Journey Wise
Summary: This study found poor agreement between lactulose breath test (LBT) and duodenal aspiration (DA) in the evaluation of small intestinal bacterial overgrowth (SIBO). LBT may be more favorable than DA due to being safer, cheaper, and less likely to yield a contaminated result. Patients with diabetes mellitus or proton pump inhibitor (PPI) use were more likely to have a positive result in DA, while those with a history of small bowel resection were more likely to have a positive result in LBT.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Review
Gastroenterology & Hepatology
Benson T. Massey, Arnold Wald
Summary: The increased availability of noninvasive breath tests has led to widespread testing for small intestinal bacterial overgrowth. The glucose breath test should be exclusively employed for diagnosing SIBO, while the lactulose breath test should be discarded.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Jin Lee, Chang-Nyol Paik, Dae Bum Kim, Ji Min Lee, Yeon-Ji Kim, Sik Kyung Choi, Yeon Jong Cho
Summary: Small intestinal bacterial overgrowth (SIBO) is not uncommon in children and adolescents with functional abdominal pain disorders (FAPDs). Age (≥12 years) and loose stool were significantly more common in children with SIBO, while the history of allergies was less common in this group. Further studies are needed to investigate the association between intestinal bacteria and history of allergy.
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY
(2022)
Review
Biochemistry & Molecular Biology
Adela Danau, Laura Dumitrescu, Antonia Lefter, Delia Tulba, Bogdan Ovidiu Popescu
Summary: There is a close connection between the gut microbiota and the brain via the gut-brain axis, with Small Intestinal Bacterial Overgrowth (SIBO) potentially playing a role in the progression of Parkinson's disease (PD). SIBO can be eradicated with antibiotics, but may reappear if predisposing factors persist, highlighting its potential impact on the development of PD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Rajesh Sanjeevi, Kapil Dev Jamwal, Sudipta Dhar Howdhury, Balamurugan Ramadass, R. Gayathri, Amit Kumar Dutta, Anjilivelil Joseph Joseph, Balakrishnan S. Ramakrishna, Ashok Chacko
Summary: SIBO is not uncommon in chronic pancreatitis patients, with GHBT showing high specificity in its diagnosis.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Daniel Bushyhead, Eamonn M. Quigley
Summary: The concept of SIBO has undergone significant changes and challenges, with uncertainty and controversy surrounding its diagnosis. This review aims to discuss the current pathophysiology of SIBO.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
(2021)
Article
Medicine, General & Internal
Changhao Dong, Rui Xian, Guangxiang Wang, Lihong Cui
Summary: The purpose of this study was to investigate the prevalence of small intestinal bacterial overgrowth (SIBO) in patients with gallbladder polyps (GBPs) and explore the possible association between the two conditions. The study found that the prevalence of SIBO was significantly higher in the GBPs group than the control group. Factors such as male gender, SIBO, fatty liver, and BMI were independently associated with GBPs. Moreover, SIBO and fasting glucose were found to be associated with solitary polyps.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Ayesha Shah, Parag Thite, Teressa Hansen, Bradley J. Kendall, David S. Sanders, Mark Morrison, Michael P. Jones, Gerald Holtmann
Summary: This study found a link between small intestinal bacterial overgrowth (SIBO) and celiac disease (CeD) through a systematic review and meta-analysis. The prevalence of SIBO is higher in CeD patients, and antibiotic therapy for SIBO positive CeD patients leads to improvement in gastrointestinal symptoms.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Cristina Duran-Rosas, Bryan Adrian Priego-Parra, Eliana Morel-Cerda, Lydia A. Mercado-Jauregui, Carlos Arturo Aquino-Ruiz, Arturo Triana-Romero, Mercedes Amieva-Balmori, Jose Antonio Velarde-Ruiz Velasco, Jose Maria Remes-Troche
Summary: This study found that a short-term 7-day PPI course induced SIBO in 7.8% of healthy subjects, with patients experiencing bloating and flatulence having a higher prevalence of developing SIBO after 7 days of treatment. Although caution against inappropriate PPI use is warranted, the benefits of PPI administration seem to outweigh the disadvantages as more than 90% of subjects did not develop SIBO after a week of treatment.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Qinyan Yao, Zihan Yu, Qingguo Meng, Jihua Chen, Yaxin Liu, Wenxuan Song, Xiangfeng Ren, Jinjie Zhou, Xin Chen
Summary: Obesity is a global public health problem with increasing occurrence worldwide. It is associated with many diseases and conditions such as NAFLD, T2DM, and IR. The gut microbiota has been recognized as an important factor in regulating host health and diseases. SIBO, a type of intestinal dysbiosis, has been found to be related to obesity and its related diseases. However, the causal relationship between SIBO and obesity and the specific mechanisms are not well understood. This review discusses the interaction between SIBO and obesity, its mechanisms, and potential interventions, aiming to discover new therapeutic targets and treatment options for obesity and its related diseases.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Infectious Diseases
Yorinobu Maeda, Teruo Murakami
Summary: Small intestinal bacterial overgrowth (SIBO) is characterized by an increase in the number and/or alteration in the type of bacteria in the upper gastrointestinal tract, causing various bowel symptoms. SIBO can be diagnosed using microbial culture or breath tests after carbohydrate ingestion. However, these methods have limitations and risks. Urinary excretion tests using bile acid conjugates have shown potential as diagnostic substrates for SIBO. PABA-UDCA disulfate offers a simple and rapid method for evaluating SIBO. Treatments for SIBO include antibiotics, probiotics, therapeutic diets, herbal medicines, and fecal microbiota transplantation.
Article
Medicine, General & Internal
Cezary Chojnacki, Tomasz Poplawski, Paulina Konrad, Michal Fila, Jan Chojnacki, Janusz Blasiak
Summary: The study indicates that the serotonin pathway of Trp metabolism may be involved in the pathogenesis of SIBO and urinary 5-HIAA concentration can serve as a potential marker for this condition. Treatment with rifaximin can reduce hydrogen levels in LHBT and 5-HIAA concentration in SIBO patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Juan Wei, Jing Feng, Liya Chen, Zhao Yang, Hui Tao, Liuying Li, Ji Xuan, Fangyu Wang
Summary: This study found a high prevalence of SIBO in patients with CD, and it was independently linked to clinical relapse in quiescent patients. Detecting SIBO may be a valuable option for the prognostic assessment of patients in clinical remission.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Juan Wei, Jing Feng, Liya Chen, Zhao Yang, Hui Tao, Liuying Li, Ji Xuan, Fangyu Wang
Summary: This study revealed a high prevalence of SIBO in patients with CD and its independent association with clinical relapse in patients in remission, with SIBO and penetrating disease behavior being the main risk factors for relapse in individuals with quiescent CD.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Angelo Armandi, Giorgia Colombo, Chiara Rosso, Gian Paolo Caviglia, Antonella Olivero, Maria Lorena Abate, Marta Guariglia, Nuria Perez Diaz del Campo, Gabriele Castelnuovo, Davide Giuseppe Ribaldone, Giorgio Maria Saracco, Armando A. Genazzani, Elisabetta Bugianesi
Summary: The expression of extracellular Nicotinamide phosphoribosyltransferase (eNAMPT) and extracellular nicotinic acid phosphoribosyltransferase (eNAPRT) varies in patients with non-alcoholic fatty liver disease (NAFLD). While eNAMPT is similarly distributed across different fibrosis stages, eNAPRT is increased in patients with advanced fibrosis and is associated with its progression. The combination of eNAPRT with other relevant factors can provide better prediction of disease progression in NAFLD patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Gian Paolo Caviglia, Angela Garrone, Chiara Bertolino, Riccardo Vanni, Elisabetta Bretto, Anxhela Poshnjari, Elisa Tribocco, Simone Frara, Angelo Armandi, Marco Astegiano, Giorgio Maria Saracco, Luciano Bertolusso, Davide Giuseppe Ribaldone
Summary: This study investigated the clinical characteristics and epidemiological changes of inflammatory bowel diseases (IBD) in the Healthcare District Bra. The prevalence and incidence of IBD have increased significantly over the past two decades, highlighting the need for specific interventions to improve patient management and resource allocation.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Angelo Armandi, Chiara Rosso, Ramy Younes, Diana Julie Leeming, Morten A. Karsdal, Gian Paolo Caviglia, Nuria Perez-Diaz-del-Campo, Daphne D'Amato, Amina Abdulle, Aurora Nicolosi, Gabriele Castelnuovo, Giorgio Maria Saracco, Davide Giuseppe Ribaldone, Elisabetta Bugianesi
Summary: This study aimed to assess the diagnostic accuracy of PRO-C3, the derivative ADAPT score, and other non-invasive tests (NITs) for advanced fibrosis in NAFLD, as well as changes over a 12-month follow-up. The results showed that serum PRO-C3 levels and ADAPT score significantly increased during the follow-up period, indicating their potential use in monitoring liver disease progression and treatment responses.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Giorgia Colombo, Gian Paolo Caviglia, Alberto Ravera, Elisa Tribocco, Simone Frara, Chiara Rosso, Cristina Travelli, Armando A. Genazzani, Davide Giuseppe Ribaldone
Summary: This study investigated the levels of eNAMPT and eNAPRT in the serum and stools of IBD patients and found that both factors were significantly increased in IBD patients and correlated with disease severity and inflammatory markers. Furthermore, serum NAMPT levels were associated with treatment failure in patients starting adalimumab therapy. Therefore, a prospective clinical trial evaluating the relationship between eNAMPT and eNAPRT levels and response to biologics in IBD patients is recommended.
FRONTIERS IN MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Alessia Ciancio, Davide Giuseppe Ribaldone, Matteo Spertino, Alessandra Risso, Debora Ferrarotti, Gian Paolo Caviglia, Patrizia Carucci, Silvia Gaia, Emanuela Rolle, Marco Sacco, Giorgio Maria Saracco
Summary: This long-term prospective cohort study identified HCV-positive patients with advanced chronic liver disease who achieved sustained virologic response after treatment with direct acting antiviral agents that can safely suspend hepatocellular carcinoma surveillance based on baseline elastographic, ultrasonographic, clinical, and biochemical features.
Review
Cardiac & Cardiovascular Systems
Fabrizio D'Ascenzo, Francesco Bruno, Mario Iannaccone, Giulia Testa, Ovidio De Filippo, Giuseppe Giannino, Gian Paolo Caviglia, Charles N. Bernstein, Gaetano Maria De Ferrari, Elisabetta Bugianesi, Angelo Armandi, Davide Giuseppe Ribaldone
Summary: This study systematically reviewed the published literature on the risk of myocardial infarction (MI) in inflammatory bowel disease (IBD) patients and found that despite a lower prevalence of classic risk factors for MI, both Crohn's disease (CD) and ulcerative colitis (UC) patients are at increased risk of MI.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Davide Giuseppe Ribaldone, Sophie Vieujean, Mette Julsgaard, Angelo Armandi, Fabiana Zingone, Edoardo Savarino, Fiorella Canete, Annalisa Aratari, Nicola Imperatore, Laura Ramos, Rocio Plaza, Daniela Pugliese, Brigida Barberio, David Drobne, Maria Chaparro
Summary: This study collected 33 cases of solid organ transplantation in patients with inflammatory bowel disease (IBD). The results showed that solid organ transplantation does not seem to impact the severity of IBD. However, further investigation is needed to examine the risk of malignancy in transplantation.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Piotr Eder, Bram Verstock, Emma Culver, Gabriele Dragoni, Lea Isabell Kredel, Joanna Wypych, Ana Garcia Garcia de Paredes, Magdalena Kaniewska, Haim Leibovitzh, Triana Lobaton, Marie Truyens, Grzegorz Oracz, Davide Giuseppe Ribaldone, Teresa Starzynska, Abdenor Badaoui, Jean-Francois Rahier, Cristina Bezzio, Peter Bossuyt, Katherine Falloon, Daniela Pugliese, Catherine Frakes Vozzo, Tine Jess, Lone Larsen, Soren Schou Olensen, Partha Pal, Maria Chaparro, Dikla Dror, Pierre Ellul, Iga Gromny, Maria Janiak, Katarzyna Maciejewska, Noam Peleg, Ariella Bar-Gil Shitrit, Lukasz Szwed, Renata Talar-Wojnarowska, Yifat Snir, Roni Weisshof, Eran Zittan, Izabela Miechowicz, Idan Goren
Summary: This study investigated the long-term outcomes of autoimmune pancreatitis (AIP) and inflammatory bowel disease (IBD) in patients with coexisting AIP-IBD, as well as the predictors of complicated AIP course. The majority of patients had type 2 AIP and colonic IBD, and the AIP course was relatively benign with favorable prognosis, but a quarter of the patients developed pancreatic complications. Age, family history, and CD were identified as potential predictors of uncomplicated AIP course.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Medicine, General & Internal
Giovanni C. Actis, Rinaldo Pellicano, Sharmila Fagoonee, Davide G. Ribaldone
Summary: This passage mainly discusses the threat of the newly described SARS-CoV-2 respiratory virus and the importance of addressing it.
Review
Medicine, General & Internal
Rinaldo Pellicano, Arianna Ferro, Francesca Cicerchia, Simone Mattivi, Sharmila Fagoonee, Marilena Durazzo
Summary: Autoimmune hepatitis (AIH) is a chronic immune-inflammatory disease of the liver that is generally considered rare. It has a wide range of clinical manifestations from mild symptoms to severe hepatitis. Chronic liver damage leads to inflammation and oxidative stress, resulting in fibrosis and even cirrhosis. Liver biopsy is the gold standard for diagnosing fibrosis, but there are also serum biomarkers, scoring systems, and radiological methods available for diagnosis and staging. The goal of AIH treatment is to suppress fibrotic and inflammatory activities in the liver to prevent disease progression and achieve complete remission. Classic steroidal anti-inflammatory drugs and immunosuppressants are commonly used, but there are also new alternative drugs being researched.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Tamas Resal, Peter Bacsur, Csilla Keresztes, Anita Balint, Renata Bor, Anna Fabian, Bernadett Farkas, Kostas Katsanos, George Michalopoylos, Davide Giuseppe Ribaldone, Mohamed Attauabi, Mirabella Zhao, Hadar Amir Barak, Henit Yanai, Cristina Bezzio, Antonio Rispo, Fabiana Castiglione, Ariella Bar-Gil Shitrit, Daniela Pugliese, Alessandro Armuzzi, Edoardo Vincenzo Savarino, Martin Kolar, Milan Lukas, Elena Chashkova, Rafal Filip, Aurore Rozieres, Stephane Nancey, Zeljko Krznaric, Eszter Schafer, Patricia Szamosi, Patricia Sarlos, Matej Franko, David Drobne, Oleg Knyazev, Anna Kagramanova, Jimmy Limdi, Panu Wetwittayakhlang, Peter L. Lakatos, Nitsan Maharshak, Lian Bannon, Tibor Nyari, Zoltan Szepes, Klaudia Farkas, TFB Study Grp, Tamas Molnar
Summary: Background and Aims: This retrospective, international cohort study aimed to evaluate the efficacy and safety of tofacitinib (TFB) in the treatment of moderate-to-severe colitis and acute severe ulcerative colitis (ASUC). The study found that TFB was effective in both indications and resulted in high rates of steroid-free remission in the short and long terms.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Nutrition & Dietetics
Gabriele Castelnuovo, Nuria Perez-Diaz-del-Campo, Chiara Rosso, Marta Guariglia, Angelo Armandi, Aurora Nicolosi, Gian Paolo Caviglia, Elisabetta Bugianesi
Summary: This study found that late chronotype and low adherence to the Mediterranean diet were associated with an increased risk of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
Article
Gastroenterology & Hepatology
Nuria Perez-Diaz-del-Campo, Gian Paolo Caviglia, Giorgia La Piana, Marta Vernero, Valentina Schillaci, Angelo Armandi, Francesco Stalla, Demis Pitoni, Elisabetta Bugianesi, Alessia Ciancio, Paola Cavalla, Davide Giuseppe Ribaldone
Summary: This study evaluated the association between inflammatory bowel disease (IBD) and multiple sclerosis (MS) and found that the risk of developing MS is similar in IBD patients compared to the general population. However, female IBD patients have a higher risk of developing MS. Additionally, the study showed that the life expectancy is lower for patients with both IBD and MS compared to those with IBD alone.
GASTROINTESTINAL DISORDERS
(2023)
Letter
Gastroenterology & Hepatology
Giovanni Clemente Actis, Rinaldo Pellicano, Davide Giuseppe Ribaldone
TURKISH JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Nutrition & Dietetics
Amedeo De Nicolo, Jessica Cusato, Cristina Bezzio, Simone Saibeni, Marta Vernero, Michela Disabato, Gian Paolo Caviglia, Alice Ianniello, Alessandra Manca, Antonio D'Avolio, Davide Giuseppe Ribaldone
Summary: This study found that VD supplementation, therapy with monoclonal antibodies, and the use of mesalazine may independently predict SARS-CoV-2 positivity in IBD patients. Hypertension was associated with severe disease, while a VD level higher than 30 ng/mL was associated with asymptomatic infection. These results confirm the importance of VD levels in defining the risk of COVID-19 and give encouraging data about the safety of maintaining immunomodulatory treatments for IBD during the COVID-19 pandemic.